Table 3

Prevalence of antibodies against specific post-translational modifications in patients with systemic lupus erythematosus (SLE) (n=349) and healthy controls (n=108)

SLE (n=349)Healthy controls (n=108)
aU/mLn, % positiveaU/mLn, % positiveMedian difference (95% CI)
Anti-MAA35 (23–52)*101 (29)23 (18–29)3 (3)12 (7 to18)
Anti-AGE112 (51–200)*63 (18)80 (41–122)4 (4)32 (3 to 60)
Anti-CarP126 (50–206)*49 (14)35 (0–111)5 (5)91 (60 to 123)
Anti-Cit3 (2–6)22 (6)3 (2 – 6)3 (3)0 (–1 to 1)
Anti-AL8 (0–23)29 (8)4 (0–19)8 (7)4 (–2 to 9)
Anti-NT44 (0–177)17 (5)11 (0–132)8 (7)33 (–1 to 67)
  • Results are presented as n (%) or median (IQR).

  • *Statistically significant difference between patients with SLE and healthy controls (p≤0.0001).

  • AGE, advanced glycation end-product; AL, acetylated protein; aU/mL, arbitrary units per millilitre; CarP, carbamylated protein; Cit, citrullinated protein; MAA, malondialdehyde–acetaldehyde adduct; NT, nitrated protein.